Sergei I. Grivennikov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sergei I. Grivennikov has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
Vivianty Hou
Cancer Prevention and Control Program, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA
4 shared publicationsRalph Francescone
Cancer Prevention and Control Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111-2497, USA
3 shared publicationsDavid Posocco
Cancer Prevention and Control Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111-2497, USA
2 shared publicationsEkaterina K. Koltsova
Blood Cell Development and Host Defense Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania
2 shared publications- Igor P. Shilovskiy
National Research Center Institute of Immunology Federal Medical-Biological Agency of Russia, 115522 Moscow, Russia
2 shared publications - Musa Rakhimovich Khaitov
National Research Center Institute of Immunology FMBA of Russia Moscow Russian Federation
2 shared publications
Latest Publications
- 16 August 2021
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 131 (16)
Distinct mechanisms govern populations of myeloid-derived suppressor cells in chronic viral infection and cancer
Myeloid-derived suppressor cells (MDSCs) are major negative regulators of immune responses in cancer and chronic infections. It remains unclear if regulation of MDSC activity in different conditions is controlled by similar mechanisms. We compared MDSCs in mice with cancer and lymphocytic choriomeningitis virus (LCMV) infection. Chronic LCMV infection caused the development of monocytic MDSCs (M-MDSCs) but did not induce polymorphonuclear MDSCs (PMN-MDSCs). In contrast, both MDSC populations were present in cancer models. An acquisition of immune-suppressive activity by PMN-MDSCs in cancer was controlled by IRE1α and ATF6 pathways of the endoplasmic reticulum (ER) stress response. Abrogation of PMN-MDSC activity by blockade of the ER stress response resulted in an increase in tumor-specific immune response and reduced tumor progression. In contrast, the ER stress response was dispensable for suppressive activity of M-MDSCs in cancer and LCMV infection. Acquisition of immune-suppressive activity by M-MDSCs in spleens was mediated by IFN-γ signaling. However, it was dispensable for suppressive activity of M-MDSCs in tumor tissues. Suppressive activity of M-MDSCs in tumors was retained due to the effect of IL-6 present at high concentrations in the tumor site. These results demonstrate disease- and population-specific mechanisms of MDSC accumulation and the need for targeting different pathways to achieve inactivation of these cells.
- 16 August 2021
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 131 (16)
Distinct mechanisms govern populations of myeloid-derived suppressor cells in chronic viral infection and cancer
Myeloid-derived suppressor cells (MDSCs) are major negative regulators of immune responses in cancer and chronic infections. It remains unclear if regulation of MDSC activity in different conditions is controlled by similar mechanisms. We compared MDSCs in mice with cancer and lymphocytic choriomeningitis virus (LCMV) infection. Chronic LCMV infection caused the development of monocytic MDSCs (M-MDSCs) but did not induce polymorphonuclear MDSCs (PMN-MDSCs). In contrast, both MDSC populations were present in cancer models. An acquisition of immune-suppressive activity by PMN-MDSCs in cancer was controlled by IRE1α and ATF6 pathways of the endoplasmic reticulum (ER) stress response. Abrogation of PMN-MDSC activity by blockade of the ER stress response resulted in an increase in tumor-specific immune response and reduced tumor progression. In contrast, the ER stress response was dispensable for suppressive activity of M-MDSCs in cancer and LCMV infection. Acquisition of immune-suppressive activity by M-MDSCs in spleens was mediated by IFN-γ signaling. However, it was dispensable for suppressive activity of M-MDSCs in tumor tissues. Suppressive activity of M-MDSCs in tumors was retained due to the effect of IL-6 present at high concentrations in the tumor site. These results demonstrate disease- and population-specific mechanisms of MDSC accumulation and the need for targeting different pathways to achieve inactivation of these cells.
- Top Cited Papers
Inflammation and Cancer: Triggers, Mechanisms, and Consequences
- 1 December 2016
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 168, 98-112
Chemokines, cytokines and exosomes help tumors to shape inflammatory microenvironment
- 1 December 2016
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 168, 98-112
Chemokines, cytokines and exosomes help tumors to shape inflammatory microenvironment
- Open Access
- 24 October 2016
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 38 (1) , 51-63
Anti-inflammatory natural product goniothalamin reduces colitis-associated and sporadic colorectal tumorigenesis
The tumor microenvironment offers multiple targets for cancer therapy, including pro-tumorigenic inflammation. Natural compounds represent an enormous source of new anti-inflammatory and anticancer agents. We previously showed that the styryl lactone goniothalamin (GTN) has promising antiproliferative and anti-inflammatory activities. Because inflammation is a major driver of colorectal cancer (CRC), we therefore evaluated the therapeutic and preventive potentials of GTN in colitis, colitis-associated cancer (CAC) and spontaneous CRC. First, in a simplistic model of inflammation in vitro, GTN was able to inhibit cytokine production in bone marrow-derived macrophages induced by lipopolysaccharide. Next, in dextran sulfate sodium (DSS) induced-colitis model, mice treated with GTN displayed restored tissue architecture, increased cell proliferation in the colonic crypts and reduced epithelial damage. Moreover, colon tissue from GTN-treated mice had significantly less expression of the inflammatory genes interleukin 1β (IL-1β), tumor necrosis factor α (TNF-α), interleukin 6 (IL-6), S100A9, interleukin 23A (IL-23A), IL-22 and IL-17A. In the azoxymethane/DSS model of CAC, GTN reduced tumor multiplicity, load and size. Additionally, GTN suppressed production of IL-6, IL-17 and TNF-α in tumor tissue, as well as abrogated stromal immune cell activation and nuclear translocation of NF-κB. Finally, in a tamoxifen inducible model of sporadic CRC, GTN-treated mice had significantly fewer tumors and decreased levels of IL-17A, IL-6, S100A9 and TNF-α protein within the tumors. These results suggest that GTN possesses anti-inflammatory and antitumor activities and represents a preventive and therapeutic agent modulating the inflammatory environment in the colon during colitis as well as CAC and CRC development.
- 24 October 2016
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 38 (1) , 51-63
Open AccessAnti-inflammatory natural product goniothalamin reduces colitis-associated and sporadic colorectal tumorigenesis
The tumor microenvironment offers multiple targets for cancer therapy, including pro-tumorigenic inflammation. Natural compounds represent an enormous source of new anti-inflammatory and anticancer agents. We previously showed that the styryl lactone goniothalamin (GTN) has promising antiproliferative and anti-inflammatory activities. Because inflammation is a major driver of colorectal cancer (CRC), we therefore evaluated the therapeutic and preventive potentials of GTN in colitis, colitis-associated cancer (CAC) and spontaneous CRC. First, in a simplistic model of inflammation in vitro, GTN was able to inhibit cytokine production in bone marrow-derived macrophages induced by lipopolysaccharide. Next, in dextran sulfate sodium (DSS) induced-colitis model, mice treated with GTN displayed restored tissue architecture, increased cell proliferation in the colonic crypts and reduced epithelial damage. Moreover, colon tissue from GTN-treated mice had significantly less expression of the inflammatory genes interleukin 1β (IL-1β), tumor necrosis factor α (TNF-α), interleukin 6 (IL-6), S100A9, interleukin 23A (IL-23A), IL-22 and IL-17A. In the azoxymethane/DSS model of CAC, GTN reduced tumor multiplicity, load and size. Additionally, GTN suppressed production of IL-6, IL-17 and TNF-α in tumor tissue, as well as abrogated stromal immune cell activation and nuclear translocation of NF-κB. Finally, in a tamoxifen inducible model of sporadic CRC, GTN-treated mice had significantly fewer tumors and decreased levels of IL-17A, IL-6, S100A9 and TNF-α protein within the tumors. These results suggest that GTN possesses anti-inflammatory and antitumor activities and represents a preventive and therapeutic agent modulating the inflammatory environment in the colon during colitis as well as CAC and CRC development.
- Open Access
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , 808-810
Colitis-Associated and Sporadic Colon Cancers: Different Diseases, Different Mutations?
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , 808-810
Open AccessColitis-Associated and Sporadic Colon Cancers: Different Diseases, Different Mutations?
- 16 February 2016
- Published by Pleiades Publishing Ltd in Biochemistry (Moscow)
- Vol. 81 (2) , 80-90
Interleukins 1 and 6 as main mediators of inflammation and cancer
The idea of a potential link between cancer and inflammation was first proposed by R. Virchow in the nineteenth century. However, clear evidence regarding a key role of inflammation in oncogenesis appeared only during the last decade. Now the tumor microenvironment is commonly considered as an obligatory and significant component of almost all types of cancer, and the cells infiltrating such microenvironment are a source of inflammatory cytokines. Such cytokines play a key role in regulating inflammation during both normal immune response and developing cancer. In this review, we explore the role of two inflammatory cytokines interleukin 1 and interleukin 6 in cancer development. These cytokines have pleiotropic effects on various cell types in the tumor microenvironment, particularly being able to regulate pro-oncogenic transcription factors NF-κB and STAT3. For this reason, such cytokines influence key parameters of oncogenesis, increasing cell resistance to apoptosis, proliferation of cancer cells, angiogenesis, invasion and malignancy as well as the ability of tumor cells to respond to anticancer therapy. Here we summarize novel experimental data regarding mechanisms underlying the interaction between chronic inflammation and malignant neoplasms.
- 16 February 2016
- Published by Pleiades Publishing Ltd in Biochemistry (Moscow)
- Vol. 81 (2) , 80-90
Interleukins 1 and 6 as main mediators of inflammation and cancer
The idea of a potential link between cancer and inflammation was first proposed by R. Virchow in the nineteenth century. However, clear evidence regarding a key role of inflammation in oncogenesis appeared only during the last decade. Now the tumor microenvironment is commonly considered as an obligatory and significant component of almost all types of cancer, and the cells infiltrating such microenvironment are a source of inflammatory cytokines. Such cytokines play a key role in regulating inflammation during both normal immune response and developing cancer. In this review, we explore the role of two inflammatory cytokines interleukin 1 and interleukin 6 in cancer development. These cytokines have pleiotropic effects on various cell types in the tumor microenvironment, particularly being able to regulate pro-oncogenic transcription factors NF-κB and STAT3. For this reason, such cytokines influence key parameters of oncogenesis, increasing cell resistance to apoptosis, proliferation of cancer cells, angiogenesis, invasion and malignancy as well as the ability of tumor cells to respond to anticancer therapy. Here we summarize novel experimental data regarding mechanisms underlying the interaction between chronic inflammation and malignant neoplasms.
- 12 November 2015
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 13 (11) , 1452-1454
IMPlicating Mesenchymal Imp1 in Colitis-Associated Cancer
Chronic inflammation and associated pathways are significant facilitators of many disease states, including malignancies. In the context of cancer, fibroblasts can actively regulate both inflammation and carcinogenesis. In this issue, Hamilton and colleagues describe a fibroblast-specific role of the RNA binding protein Imp1 in suppression of intestinal inflammatory responses and development of colitis-associated cancer. Mol Cancer Res; 13(11); 1452–4. ©2015 AACR.
- 12 November 2015
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 13 (11) , 1452-1454
IMPlicating Mesenchymal Imp1 in Colitis-Associated Cancer
Chronic inflammation and associated pathways are significant facilitators of many disease states, including malignancies. In the context of cancer, fibroblasts can actively regulate both inflammation and carcinogenesis. In this issue, Hamilton and colleagues describe a fibroblast-specific role of the RNA binding protein Imp1 in suppression of intestinal inflammatory responses and development of colitis-associated cancer. Mol Cancer Res; 13(11); 1452–4. ©2015 AACR.
- 20 September 2015
- Published by Springer Nature
- p. 189-209
Microbiome Implications in Intestinal Tumorigenesis
- 20 September 2015
- Published by Springer Nature
- p. 189-209
Microbiome Implications in Intestinal Tumorigenesis
- Open Access
- 1 February 2015
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 21 (2) , 409-418
Cytokines, IBD, and Colitis-associated Cancer
Inflammatory bowel diseases (IBDs) are debilitating conditions that result in intestinal damage due to chronic inflammation. In addition, the perpetua
- 1 February 2015
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 21 (2) , 409-418
Open AccessCytokines, IBD, and Colitis-associated Cancer
Inflammatory bowel diseases (IBDs) are debilitating conditions that result in intestinal damage due to chronic inflammation. In addition, the perpetua